MRC Stock Overview
Mercator Medical S.A., together with its subsidiaries, manufactures and distributes disposable medical gloves, dressings, and non-woven fabric products in Europe and internationally.
Mercator Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||zł48.50|
|52 Week High||zł168.35|
|52 Week Low||zł45.10|
|1 Month Change||-15.45%|
|3 Month Change||-7.20%|
|1 Year Change||-67.88%|
|3 Year Change||789.91%|
|5 Year Change||201.24%|
|Change since IPO||231.06%|
Recent News & Updates
Returns At Mercator Medical (WSE:MRC) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
|MRC||PL Medical Equipment||PL Market|
Return vs Industry: MRC underperformed the Polish Medical Equipment industry which returned -45.8% over the past year.
Return vs Market: MRC underperformed the Polish Market which returned -32.1% over the past year.
|MRC Average Weekly Movement||10.7%|
|Medical Equipment Industry Average Movement||10.3%|
|Market Average Movement||6.1%|
|10% most volatile stocks in PL Market||11.7%|
|10% least volatile stocks in PL Market||3.8%|
Stable Share Price: MRC is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: MRC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
Mercator Medical S.A., together with its subsidiaries, manufactures and distributes disposable medical gloves, dressings, and non-woven fabric products in Europe and internationally. The company offers surgical and protective, sterile examination and protective, and household gloves; glove brackets; and single-use clothing, including caps, masks, gowns, shoe covers, surgical shirts, sleeve protectors, and patient’s shirts. It also provides surgical drape sheets; sterile drapes with non-adhesive opening; surgical sets; and accessories, such as apparatus covers, limb protectors, table covers, camera covers, adhesive pockets for surgical instruments, and self-adhesive nonwoven tapes.
Mercator Medical Fundamentals Summary
|MRC fundamental statistics|
Is MRC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MRC income statement (TTM)|
|Cost of Revenue||zł879.18m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Sep 30, 2022
|Earnings per share (EPS)||15.72|
|Net Profit Margin||12.75%|
How did MRC perform over the long term?See historical performance and comparison
Is MRC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MRC?
Other financial metrics that can be useful for relative valuation.
|What is MRC's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does MRC's PE Ratio compare to its peers?
|MRC PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
EMC EMC Instytut Medyczny
SNT Synektik Spólka Akcyjna
MRC Mercator Medical
Price-To-Earnings vs Peers: MRC is good value based on its Price-To-Earnings Ratio (3.1x) compared to the peer average (54.3x).
Price to Earnings Ratio vs Industry
How does MRC's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: MRC is good value based on its Price-To-Earnings Ratio (3.1x) compared to the European Medical Equipment industry average (24.7x)
Price to Earnings Ratio vs Fair Ratio
What is MRC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||3.1x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MRC's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of MRC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MRC (PLN48.5) is trading below our estimate of fair value (PLN83.07)
Significantly Below Fair Value: MRC is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Mercator Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mercator Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Mercator Medical is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Mercator Medical competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Mercator Medical performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRC has high quality earnings.
Growing Profit Margin: MRC's current net profit margins (12.8%) are lower than last year (54.7%).
Past Earnings Growth Analysis
Earnings Trend: MRC's earnings have grown significantly by 67.3% per year over the past 5 years.
Accelerating Growth: MRC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MRC had negative earnings growth (-86%) over the past year, making it difficult to compare to the Medical Equipment industry average (2%).
Return on Equity
High ROE: MRC's Return on Equity (14.2%) is considered low.
Discover strong past performing companies
How is Mercator Medical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MRC's short term assets (PLN912.9M) exceed its short term liabilities (PLN132.0M).
Long Term Liabilities: MRC's short term assets (PLN912.9M) exceed its long term liabilities (PLN10.6M).
Debt to Equity History and Analysis
Debt Level: MRC is debt free.
Reducing Debt: MRC has no debt compared to 5 years ago when its debt to equity ratio was 43.7%.
Debt Coverage: MRC has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MRC has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Mercator Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MRC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MRC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: MRC is not paying a notable dividend for the Polish market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MRC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wieslaw Zyznowski (58 yo)
Dr. Wies aw yznowski, Phd., serves as the Chairman of Management Board at Mercator Medical Splka Akcyjna since 2010. In the 90s Dr. yznowski co-founded the Mercator. From 1991 to 2001 he served as (apar...
CEO Compensation Analysis
Compensation vs Market: Wieslaw's total compensation ($USD911.53K) is above average for companies of similar size in the Polish market ($USD253.24K).
Compensation vs Earnings: Wieslaw's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: MRC's management team is considered experienced (2.3 years average tenure).
Experienced Board: MRC's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Mercator Medical S.A.'s employee growth, exchange listings and data sources
- Name: Mercator Medical S.A.
- Ticker: MRC
- Exchange: WSE
- Founded: 1989
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: zł516.388m
- Shares outstanding: 10.65m
- Website: https://mercatormedical.eu
Number of Employees
- Mercator Medical S.A.
- ul. Heleny Modrzejewskiej 30
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MRC||WSE (Warsaw Stock Exchange)||Yes||Bearer Shares||PL||PLN||Jan 2014|
|0QJM||LSE (London Stock Exchange)||Yes||Bearer Shares||GB||PLN||Jan 2014|
|MM2||BST (Boerse-Stuttgart)||Yes||Bearer Shares||DE||EUR||Jan 2014|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/24 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.